Honma M, Hayashi K. Psoriasis: recent progress in molecular-targeted therapies. J Dermatol. 2021;48:761–77.

PubMed  Google Scholar 

Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol. 2017;13:15–26.

CAS  PubMed  Google Scholar 

Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344–54.

CAS  PubMed  PubMed Central  Google Scholar 

Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15:35–50.

CAS  PubMed  Google Scholar 

Howell MD, Fitzsimons C, Smith PA. JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease. Ann Allergy Asthma Immunol. 2018;120:367–75.

CAS  PubMed  Google Scholar 

Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–48.

CAS  PubMed  Google Scholar 

Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184:857–70.

CAS  PubMed  Google Scholar 

• Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35:464–75. This study demonstrated safety and efficacy in patients down to 6 months of age, expanding dupilumab’s indication and allowing for an efficacious treatment option in young pediatric patients.

CAS  PubMed  Google Scholar 

Albader SS, Alharbi AA, Alenezi RF, Alsaif FM. Dupilumab side effect in a patient with atopic dermatitis: a case report study. Biologics. 2019;13:79–82.

PubMed  PubMed Central  Google Scholar 

Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86:628–36.

CAS  PubMed  Google Scholar 

Raffi J, Suresh R, Fishman H, Botto N, Murase JE. Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD). Int J Womens Dermatol. 2019;5:308–13.

PubMed  PubMed Central  Google Scholar 

Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155:850–2.

PubMed  PubMed Central  Google Scholar 

Maloney NJ, Tegtmeyer K, Zhao J, Worswick S. Dupilumab in dermatology: potential for uses beyond atopic dermatitis. J Drugs Dermatol. 2019;18.

Office of the Commissioner FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder. In: U.S. Food and Drug Administration. 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder. Accessed 27 Jul 2022

Hewett L. LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis. 2021. https://nationaleczema.org/blog/leo-122821/. Accessed 27 Jul 2022.

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437–49.

CAS  PubMed  Google Scholar 

Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186:440–52.

CAS  PubMed  Google Scholar 

Wollenberg A, Beck LA, de Bruin WM, Simpson EL, Imafuku S, Boguniewicz M, Zachariae R, Olsen CK, Thyssen JP. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186:453–65.

CAS  PubMed  Google Scholar 

Agboola F, Atlas SJ, Brouwer E, Carlson JJ, Hansen RN, Herron-Smith S, Nhan E, Rind DM, Pearson SD. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value. J Manag Care Spec Pharm. 2022;28:108–14.

PubMed  Google Scholar 

Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158:523–32.

PubMed  PubMed Central  Google Scholar 

Safety and efficacy of lebrikizumab (LY3650150) in combination with topical corticosteroid in moderate-to-severe atopic dermatitis. - Study results - ClinicalTrials.gov. 2022. https://clinicaltrials.gov/ct2/show/results/NCT04250337?id=NCT04250337&draw=2&rank=1&load=cart. Accessed 25 Jul 2022.

Evaluation of the efficacy and safety of lebrikizumab (LY3650150) in moderate to severe atopic dermatitis (ADvocate1). 2022. https://clinicaltrials.gov/ct2/show/NCT04146363. Accessed 25 Jul 2022.

Labib A, Ju T, Yosipovitch G. Managing atopic dermatitis with lebrikizumab - the evidence to date. Clin Cosmet Investig Dermatol. 2022;15:1065–72.

PubMed  PubMed Central  Google Scholar 

Chu C-Y. Treatments for childhood atopic dermatitis: an update on emerging therapies. Clin Rev Allergy Immunol. 2021;61:114–27.

CAS  PubMed  Google Scholar 

Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2020;174:29–37.

PubMed  Google Scholar 

Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, Nadeau KC. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162:89–93.

CAS  PubMed  Google Scholar 

Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8:990–8.

PubMed  Google Scholar 

Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, Peng X, Wen HC, Govas P, Gudi G, Ca V, Fang H, Salhi Y, Back J, Reddy V, Bissonnette R, Maari C, Grossman F, Wolff G. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(2):482-493.e7. https://doi.org/10.1016/j.jaci.2018.11.053 . Epub 2019 Feb 6 PMID: 30738171.

Article  CAS  PubMed  Google Scholar 

Simpson EL, Imafuku S, Poulin Y, et al. A phase 2 randomized trial of apremilast in patients with atopic dermatitis. J Invest Dermatol. 2019;139:1063–72.

CAS  PubMed  Google Scholar 

Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494-503.e6.

CAS  PubMed  Google Scholar 

Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21:275–84.

PubMed  PubMed Central  Google Scholar 

Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151–68.

CAS  PubMed  Google Scholar 

• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157:1047–55. This clinical trial demonstrated superiority of upadacitinib when compared head-to-head with dupilumab.

PubMed  PubMed Central  Google Scholar 

Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400:273–82.

CAS  PubMed  Google Scholar 

Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157:1165–73.

PubMed  Google Scholar 

Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85:62–70.

CAS  PubMed  Google Scholar 

Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35:476–85.

CAS  PubMed  Google Scholar 

Updates on OLUMIANT® (baricitinib) phase 3 lupus program and FDA review for atopic dermatitis. In: Eli Lilly and Company. 2022. https://investor.lilly.com/news-releases/news-release-details/updates-olumiantr-baricitinib-phase-3-lupus-program-and-fda. Accessed 23 Jul 2022.

Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85:863–72.

CAS  PubMed  Google Scholar 

Center for Drug Evaluation Research FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older. In: U.S. Food and Drug Administration. 2022. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older. Accessed 10 Aug 2022.

Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148:927–40.

CAS  PubMed  Google Scholar 

Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902–11.

CAS  PubMed  Google Scholar 

Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82:823–31.

CAS  PubMed  Google Scholar 

Yosipovitch G, Ständer S, Kerby MB, Larrick JW, Perlman AJ, Schnipper EF, Zhang X, Tang JY, Luger T, Steinhoff M. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol. 2018;78:882-891.e10.

CAS  PubMed  Google Scholar 

Welsh SE, Xiao C, Kaden AR, et al. Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial. J Eur Acad Dermatol Venereol. 2021;35:e338–40.

CAS  PubMed  PubMed Central  Google Scholar 

• Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M. Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther. 2021;11:885–905. This is a large-scale systemic review that evaluated the clinical advantages of some of the most recently approved biologic